Organicell (BPSR) a Triple Since Easter.
Slowly she turns, step-by-step. $20 million gain in market value. Spurred by FDA Emergency IND's.
RELATED: Adding Organicell (BPSR) $0.02 to the Watch List.
FDA Approves...
Citius Pharma (CTXR) Seeks Expeditious Pathway Into the Clinic, for CoronaVirus Related Acute Respiratory...
Sumbmits pre-IND Into Coronavirus Treatment Acceleration Program (CTAP).
Citius Announces Pre-IND Submission to FDA Under the Coronavirus Treatment Acceleration Program for a Novel Stem...
‘Amazing potential.’ UM doctor to start stem cell trial for coronavirus patients (Miami Herald)
BY BEN CONARCK APRIL 16, 2020
A team of doctors at the University of Miami won emergency federal approval to use stem cell therapy on...
FDA Authorizes Athersys (ATHX) to Initiate a Pivotal Clinical Trial!
FDA Authorizes Athersys to Initiate a Pivotal Clinical Trial Evaluating MultiStem® Cell Therapy in Patients With COVID-19 Induced Acute Respiratory Distress Syndrome.
(Editors note: a...
Latest article
Latest Research Report: $20 Price Target from Greenridge Global.
Here are four research reports below to peruse, all with price targets $20.00 or more...
While we don't issue price targets, it's comforting to see...
Three More Companies Suspended by SEC!
Millions of Investor's Dollars are Being Trapped.
These three companies had a combined market cap of $563 million at the time they were halted, whose...
AI Data Center Short – Jim Chanos
“If the economic life on these things is three years ... the whole economics of a lot of these deals kind of falls...
